康辰药业：KC1086项目获得FDA批准开展临床试验

Core Viewpoint - Kangchen Pharmaceutical (603590.SH) has received FDA approval for its clinical trial application for KC1086 tablets, a novel small molecule inhibitor targeting Lysine Acetyltransferase 6 (KAT6) for the treatment of advanced recurrent or metastatic solid tumors [2] Company Summary - The drug KC1086 is fully developed by Kangchen Pharmaceutical and features a new structure with high potency and selectivity [2] - The clinical trial for KC1086 is currently progressing in an orderly manner [2]